<DOC>
	<DOCNO>NCT01617434</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North South America . The aim trial investigate effect liraglutide versus placebo add basal insulin analogue without metformin subject type 2 diabetes .</brief_summary>
	<brief_title>The Effect Liraglutide Versus Placebo When Added Basal Insulin Analogues With Without Metformin Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed type 2 diabetes least 180 day prior screen treat stable basal insulin analogue dose minimum 20 U/day without stable metformin equal 1500 mg/day least 8 week prior screen ( defined insulin adjustment less 10 % past 8 week assess investigator ) HbA1c ( glycosylated haemoglobin A1c ) 7.010.0 % ( inclusive ) Body mass index ( BMI ) 2045 kg/m^2 ( inclusive ) Female childbearing potential pregnant , breastfeed intend become pregnant Recurrent severe hypoglycaemic episode hypoglycaemic unawareness Treatment glucoselowering agent ( ) state inclusion criterion period 12 week prior screen Impaired liver renal function Uncontrolled treat untreated hypertension ( systolic blood pressure ( SBP ) equal 180 mmHg and/or diastolic blood pressure ( DBP ) equal 100 mmHg ) Any clinically significant disorder , except condition associate type 2 diabetes history investigator 's opinion could interfere result trial Known suspect abuse alcohol narcotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>